Subsequently, combination of HDI with sorafenib, an inhibitor of multiple kinases including Raf-1, platelet-derived growth factor, vascular endothelial growth factor receptors 1 and 2, and FLT3, was found to induce synergistic cell death in BCR/ABL-positive cells, imatinib-resistant cells and primary CD34+ bone marrow cells from CML patients (Dasmahapatra et al, 2007). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.